IngredientsCetyl stearate is a long-chain wax ester belonging to the broader chemical family of alkyl esters. Its IUPAC name is hexadecyl octadecanoate. Other accepted names and synonyms include: octadecanoic acid, hexadecyl ester; stearic acid, hexadecyl ester; hexadecyl stearate; palmityl stearate; n-hexadecyl stearate; and trade designations such as Wickenol 121 and Schercemol CS. Its EINECS number is 214-724-1 and its CAS Registry Number is 1190-63-2.
The molecular formula of cetyl stearate is C34H68O2. Its molecular weight is 508.9 g/mol. Structurally, it is the ester formed by the condensation of cetyl alcohol (1-hexadecanol, a 16-carbon fatty alcohol) and stearic acid (octadecanoic acid, an 18-carbon saturated fatty acid). As a long-chain fatty acid ester, it presents as a white, waxy solid, insoluble in water yet dissolvable in organic solvents. Its melting point is approximately 57 °C, and its boiling point is approximately 497 °C. These physical characteristics—particularly the near-body-temperature melting range—make it compatible with skin-contact formulations. The compound is classified as a saturated wax ester due to the fully saturated carbon chains of both the acid and alcohol components.
From a molecular perspective, cetylated fatty acids (CFAs) are naturally occurring lipophilic esters derived from plant and/or animal sources, consisting of fatty acids esterified with cetyl alcohol (possessing a linear saturated C16 alkyl chain). Cetyl stearate is one member of this broader CFA family. Cetylated fatty acids (CFAs) comprise a group of naturally occurring fatty acids from vegetable origin; this group includes compounds such as cetyl myristate, cetyl palmitate, and cetyl oleate, among others. Cetyl stearate is the specific ester in which stearic acid (C18:0) is paired with cetyl alcohol (C16:0), making it one of the more fully saturated members of the class.
Cetyl stearate occurs naturally as a minor but characteristic component of spermaceti, the waxy substance extracted from sperm whales (Physeter macrocephalus). Wax esters are prominent in the spermaceti organ of sperm whales, where they constitute 65–95% of the organ's lipid content, primarily as cetyl palmitate (approximately 38.8%), cetyl myristate (37.7%), cetyl laurate (15.3%), and cetyl stearate (8.2%). This waxy substance fills the large cavity in the whale's head, aiding buoyancy control by altering density in response to temperature and pressure changes during dives.
Waxes are esters of long-chain fatty acids and long-chain alcohols, whose principal natural sources are animals (sperm whale oil) and vegetables (jojoba), though both are expensive and not easily available. Wax esters synthesized by enzymatic transesterification, using palm stearin as raw material, can be considered as an alternative to natural ones. Specifically, palm stearin—a solid fraction obtained by fractionation of palm oil—can be esterified with cetyl alcohol to produce a mixture of wax esters, using an immobilized lipase from Rhizopus oryzae as biocatalyst. HPLC analysis of palm stearin wax esters has confirmed that the four main wax esters produced are cetyl palmitate, cetyl stearate, cetyl oleate, and cetyl linoleate.
Wax esters are widely distributed among many phylogenetic taxa, occurring in animals, plants, and microorganisms; reflective of their chemical inertness, wax esters serve roles as either chemical forms of energy storage (e.g., jojoba seed oil and spermaceti oil), or as structural water barriers (e.g., cuticle components and beeswax). Wax esters are formed by the reaction between a fatty alcohol and a fatty acyl-CoA, and biological systems appear to have evolved three families of enzymes to catalyze this reaction.
Commercial cetyl stearate is typically produced by direct chemical esterification—reacting stearic acid with cetyl alcohol in the presence of an acid catalyst—or by enzymatic transesterification. Rich sources of wax esters historically included whale oil, 95% of which is composed of wax esters; spermaceti oil from the head of sperm whales was prized in cosmetics, candle making, lubricants, and pharmaceuticals. Once whaling was internationally banned in the 1980s, alternatives were developed. Today, the ingredient is produced synthetically or via enzyme-catalyzed reactions using plant-derived starting materials. Cetyl stearate is classified as a wax ester of stearic acid.
Prior to modern synthesis, cetyl stearate was encountered primarily as a minor component of spermaceti wax. Spermaceti was applied to watches, clocks, and early machinery; a cetyl ester wax derived from vegetable sources such as coconut or palm oils now serves as the primary alternative, replicating the emollient and stabilizing properties of the original spermaceti. Historically, spermaceti was employed in pharmacopeial preparations—cold creams, ointments, lip balms, and suppository bases—where its waxy texture, skin-compatibility, and near-body-temperature melting point made it ideal. Cetyl stearate, as a constituent of spermaceti, participated in those functions without being explicitly distinguished as an independent ingredient.
Cetyl stearate, a waxy ester derived from cetyl alcohol and stearic acid, has a history of use in both traditional and modern medicinal applications; though its primary recognition is as an emulsifying and stabilizing agent, its origins in natural fatty acids have made it a valued component in remedies intended to soothe and protect the body's tissues; historically, natural stearates have been found in herbal preparations and topical balms, where they contributed to the smooth texture and enhanced absorption of potent plant extracts. This facilitated the delivery of herbal actives in skin care and wound-healing salves, often used for their ability to form protective barriers and maintain skin hydration.
Historically, inclusion of cetyl stearate in nutritional products has been driven more by its functional properties—improving texture, stability, and palatability of formulations—rather than direct physiological effects. No documented traditional medicinal system (Ayurveda, Traditional Chinese Medicine, Indigenous American traditions) specifically identified or deliberately prepared cetyl stearate as a standalone therapeutic agent. Its traditional use is thus best understood as implicit—embedded in preparations made from natural fats and waxes—rather than as a consciously isolated compound.
Cetyl myristoleate (CM), as an arthritis palliative, was discovered by Harry Diehl in 1964, who showed that CM protected Swiss albino mice from arthritis, as well as laboratory rats exposed to Freund's adjuvant. In 2001, a new formulation containing cetylated fatty ester complex (CFEC; also known as esterified fatty ester complex or EFAC) began to be used for arthritic and sports injury-related conditions. Cetyl stearate is one member of the CFA mixtures studied in this context.
At the molecular level, wax esters represent esters of fatty alcohols and fatty acids, and a large variety of combinations is possible, including medium, long, and very long chain lengths as well as various degrees of unsaturation of the fatty alcohol and fatty acid partners. Cetyl stearate is notable for being fully saturated on both the alcohol and acid portions, conferring high chemical stability and solid-state properties at room temperature. As a long-chain fatty acid ester, it frequently finds use in the cosmetics sector and various industries.
Both constituent components of cetyl stearate—cetyl alcohol (1-hexadecanol) and stearic acid (octadecanoic acid)—are endogenous to mammalian metabolism. Stearic acid is a common saturated fatty acid found in animal and plant fats. Cetyl alcohol occurs naturally in small amounts in body tissues. As an ester, cetyl stearate is hydrolyzed by esterases and lipases to yield these two components, which can then be processed through normal fatty acid metabolic pathways.
Cetyl stearate is typically encountered in research and commercial preparations not as an isolated compound but as part of multi-component cetylated fatty acid blends. Celadrin is a patented combination of cetylated, esterified fatty acids containing cetyl myristoleate, cetyl myristate, cetyl palmitoleate, cetyl laureate, cetyl palmitate, and cetyl oleate extracted from plant-based sources, with oils including palm, palm kernel, olive, nutmeg, coconut, and unsaturated vegetable oils. Cetyl stearate may appear in related formulations or as a minor component in such blends.
A mechanism proposed in 1994 suggested that CFAs exert their effects by stabilizing cell membranes and protecting synovial tissues; these actions were proposed to help maintain normal joint flexibility and mobility, alleviate pain, and enhance the production of joint fluid, thereby supporting proper lubrication. However, more specific molecular targets that explain their mechanism of action have not yet been identified.
Cetylated fatty acids are believed to work in a similar way to the essential fatty acids from fish oil, enhancing the integrity of cell membranes and reducing inflammation. CFAs have been shown to play a role in synovial membrane protection and cell membrane stabilization, promoting normal flexibility and mobility, leading to a reduction in pain and an increase in joint fluidity and lubrication.
Fatty acids may induce changes in membrane fluidity, antibody and cytokine production, adhesion molecule expression, and signal transduction pathways; they may suppress leukocyte function, trigger apoptosis, and, like NSAIDs, reduce production of prostaglandins and leukotrienes. In vitro studies have shown that the cetylated fatty acids mixture from Celadrin significantly decreased the production of IL-6, MCP-1, and TNF, key regulators of the inflammatory process, in stimulated RAW264.7 mouse macrophage cells.
The mechanism of action of CFAs' analgesic and anti-inflammatory properties has not yet been clearly established; however, endocannabinoids such as 2-arachidonoylglycerol (2-AG) and anandamide (AEA) are known to produce analgesic and anti-inflammatory effects; these compounds undergo physiological inactivation by several enzymes, including monoacylglycerol lipase (MAGL); research has demonstrated for the first time that the therapeutic effects of CFAs may be attributable, at least in part, to their MAGL inhibition activities, which induce a local increase in analgesic/anti-inflammatory endocannabinoids in close proximity to the site of administration.
These findings pave the way for the development of new potent local analgesic agents whose action is based on an indirect cannabinoid effect. It should be noted that this endocannabinoid hypothesis applies to the CFA class broadly, and the specific contribution of cetyl stearate relative to other CFA members has not been individually quantified.
CFAs have been shown to promote the chondrogenic differentiation of human adipose-derived stem cells by enhancing the expression of chondrogenic markers under chondrogenic induction conditions. In animal models of osteoarthritis, histological analysis revealed a protective effect of fatty acids against cartilage degradation in treated knee joints, with a significant improvement in all articular cartilage parameters, including thickness, volume, and surface integrity. Again, these observations apply to CFA mixtures in which cetyl stearate may be present, not to cetyl stearate as a sole active ingredient.
Proponents also make multiple specific claims, including that cetylated fatty acids reduce inflammation, protect cartilage from damage, lubricate cell membranes, and increase fluid in joints; some also claim CFAs improve prostaglandin production as a mechanism to reduce inflammation and regulate the immune system; however, none of these explanations have more than limited scientific support, and if cetylated fatty acids do help osteoarthritis, their mechanism is still being studied.
A critical distinction must be established before reviewing the clinical literature. Most available research on cetyl stearate centers on its role as an excipient rather than a bioactive compound; it is a fatty acid ester formed from cetyl alcohol and stearic acid, commonly used as an emulsifier, stabilizer, and lubricant in various products including nutritional supplements and pharmaceuticals. Most research on cetyl stearate centers on its role as an excipient rather than a bioactive compound, and specific clinical studies investigating cetyl stearate's direct nutritional benefits remain limited. The clinical evidence described below largely pertains to multi-component CFA mixtures that may contain cetyl stearate among several related esters, not to cetyl stearate in isolation.
The most researched therapeutic area for CFA mixtures is knee osteoarthritis. To determine the benefit of cetylated fatty acids (CFA) on knee range of motion and function in patients with osteoarthritis (OA), sixty-four patients with chronic knee OA were evaluated at baseline and at 30 and 68 days after consuming either placebo or CFA (Celadrin); evaluations included physician assessment, knee range of motion with goniometry, and the Lequesne Algofunctional Index (LAI); after 68 days, patients treated with CFA exhibited a significant (p < 0.001) increase in knee flexion (10.1 degrees) compared to patients given placebo (1.1 degrees). Neither group reported improvement in knee extension.
A more recent randomized, double-blind, placebo-controlled trial published in the European Journal of Clinical Nutrition (2025) examined oral CFA in patients with advanced knee OA. Sixty patients (mean age 66.0 ± 7.7 years, 85% female) with grade 3–4 knee osteoarthritis and a pain intensity of >4 cm on the visual analog scale (VAS) were enrolled and randomized in a 1:1 ratio to receive either 1.5 g of oral CFA or a placebo for 60 days. The primary outcome was the change in pain intensity (VAS); secondary outcomes included changes in range of motion and WOMAC scores; after 60 days of CFA, the mean reduction in pain intensity (VAS) was −1.7 cm (95% CI [−2.0, −1.4]), showing a statistically significant difference.
A parallel-arm randomized clinical trial compared oral CFA to the NSAID meloxicam. This study aimed to assess how effective an oral form of cetylated fatty acid compounds is in improving physical function, pain, and stiffness of individuals suffering from knee osteoarthritis, and how its effectiveness compares to that of meloxicam. For this parallel-arm randomized clinical trial, 48 adult patients with knee OA were divided into two groups; the intervention group was prescribed 350 mg CFA capsule three times per day for 30 days, while the control group was given 15 mg of meloxicam one tablet daily for ten days. No adverse events were observed or reported during the trial in those treated with oral CFA, while one patient in the meloxicam group reported poor drug tolerance due to dyspepsia and was excluded.
A 2025–2026 systematic review and meta-analysis registered on PubMed synthesized evidence across multiple study types. Cetylated fatty acids (CFAs), a group of esterified fatty acids administered either topically or orally to protect the synovial membrane and stabilize cell membranes, appear to be a promising therapeutic option for knee osteoarthritis, a debilitating global health issue with effective treatments still lacking. A comprehensive search in PubMed, Embase, Cochrane Library, CENTRAL, and Web of Science from inception until November 2024 was conducted; randomized controlled trials with a CFA intervention group compared with a placebo or non-CFA treatment were included, as well as pre-post experimental studies.
A multicenter study examined short-term topical CFA in early and advanced knee OA. The study included 113 patients (32 males, 81 females; median age 70.0 years; 95% CI: 69.0–71.4 years) with knee OA diagnosed according to American College of Rheumatology classification criteria; each patient underwent knee X-rays, followed by a CFA topical treatment (two applications per day for one week); before and after treatment, patients completed a WOMAC questionnaire. Previous studies have reported that topical CFAs are effective in all knee OA patients, with slightly higher evidence for those with advanced disease.
A smaller study of 40 knee OA patients examined postural and plantar pressure changes after topical CFA. The purpose was to examine the effects of 30 days of treatment with a topical cream consisting of cetylated fatty acids on static postural stability and plantar pressures in patients with osteoarthritis of one or both knees; forty patients diagnosed with knee OA were randomly assigned to either CFA (N = 20) or placebo (N = 20) treatment groups; patients were tested at baseline and following a 30-day treatment period consisting of cream application twice per day; assessments included 20- and 40-second quiet standing protocols on a force plate to measure center of pressure total excursion length, COP velocity, and rearfoot and forefoot plantar pressure distribution.
There are no previous studies on CFAs in hand OA; patients fulfilling the American College of Rheumatology criteria for hand OA participated in a randomized, double-blind, placebo-controlled study; eligible patients were over 40 years of age, had at least one tender joint, and had a joint pain visual analog score of 30–60 mm. Patients received topical CFA (n = 36) or placebo (n = 36) twice daily for six weeks; the primary outcome was the Functional Index for Hand Osteoarthritis (FIHOA) at 2, 4, and 6 weeks. Upon concluding the 6-week study period, patients in the CFA group exhibited a notably lower mean pain score compared to those in the placebo group (2.2 ± 1.9 vs. 3.2 ± 2.2, P < 0.05) and achieved superior Patient Global Assessment scores (2.1 ± 1.7 vs. 3.1 ± 2.2, P < 0.05); however, no significant difference was detected in FIHOA between the two groups; additionally, adverse reactions were reported by two patients in the placebo group, whereas none were documented in the CFA group; topical CFAs demonstrated efficacy in alleviating pain and enhancing patient global satisfaction in the treatment of hand osteoarthritis.
Participants with Myofascial Pain Syndrome (MPS) of the neck were randomly assigned into two groups of a double-blinded study: topical cetylated fatty ester complex (CFEC) cream application plus physical therapy (CF-PT; n = 37), and placebo cream application plus physical therapy (PL-PT; n = 35); there were 3 visits during 4 weeks of treatment; physical therapy, given twice per week, included ischemic compression, deep pressure trigger point massage, and myofascial releases; topical cream (CFEC cream 5.6% and 1.5% menthol) or placebo cream (1.5% menthol in a cream base) was applied twice per day. CF-PT provided the fastest and most effective study treatment modality; the addition of CFEC cream to PT resulted in statistically significant improvements compared to PL-PT for reduction of pain, neck disability, and life quality indicators; results indicate that cetylated derivatives of fatty acids can effectively reduce pain and symptoms associated with neck MPS when combined with physical therapy.
The aim of one study was to evaluate the efficacy and tolerability of a cetylated fatty acids (CFA) patch formulation in the control of acute localized shoulder pain and recovery of function in patients with tendinopathies; it was a prospective, single-center observational study; thirty patients with recent onset shoulder pain symptoms (1–3 months) related to bursitis and tenosynovitis with a diagnosis confirmed by ultrasound examination were evaluated for shoulder pain and function using the Constant Murley Score; patients used 1 patch containing CFA for 8 hours per day for 10 days. Several clinical studies have demonstrated that CFAs, administered both topically and orally, contribute to relieving pain and improving functional performance in patients with knee and hand OA, tendinopathies such as shoulder tendon disorders, myofascial pain syndrome of the neck, axial discogenic low back pain, and sports injuries.
The shoulder tendinopathy study was a prospective observational study without a placebo arm, representing a significant limitation in establishing causality.
While some proponents claim that cetylated fatty acids can reduce inflammation and protect joint health, the scientific support for these claims remains sparse, and there have been no direct comparisons with other supplements like glucosamine; safety studies suggest a low toxicity level, however more research is needed to establish safe usage parameters, especially for vulnerable populations; overall, cetylated fatty acids present a promising area of study, but more definitive evidence is required to substantiate their therapeutic claims.
Oral and topical cetylated fatty acids are not known to have any adverse or unwanted effects while their benefits have been well-demonstrated; however, their mechanism of action has not been well-elucidated; reduced pro-inflammatory cytokine levels, changes in membrane fluidity, and signal transduction changes have been proposed.
Critically, the available human clinical trials test mixtures of cetylated fatty acids—not cetyl stearate in isolation. Trial sizes are generally small (30–113 patients), follow-up periods are short (1 week to 60 days), and independent replication is limited. Evidence is therefore best characterized as preliminary to moderate, with the most robust signals in topical and oral application for knee osteoarthritis pain.
The musculoskeletal system—specifically articular cartilage, synovial membranes, tendons, and the joints of the knee, hand, shoulder, and spine—is the primary domain in which CFA mixtures containing cetyl stearate have been studied. CFAs have been shown to promote the chondrogenic differentiation of human adipose-derived stem cells by enhancing the expression of chondrogenic markers under chondrogenic induction conditions. Research has shown that certain cetylated fatty esters act to relieve pain, improve joint mobility, and return physical function to affected joints in humans and in animal models; other non-arthritic conditions that include myofascial pain syndrome and sports-related pain injuries have also demonstrated therapeutic potential.
In the context of topical application, cetyl stearate functions as a skin-conditioning agent. In cosmetics and personal care products, stearate esters are used most frequently in the formulation of eye makeup, skin makeup, lipstick, and skin care products; stearate esters act primarily as lubricants on the skin's surface, which gives the skin a soft and smooth appearance. Cetylated fatty acid creams have also been proposed for treatment of psoriasis. Research indicates that cetylated fatty acids may have limited effectiveness for treating related conditions such as knee and shoulder pain, and there are ongoing discussions about their potential benefits for psoriasis and various autoimmune diseases.
Cetylated fatty acids have emerged as a promising class of compounds in the management of musculoskeletal disorders, demonstrating anti-inflammatory and pain-relieving properties. The proposed immune-modulating pathways (cytokine suppression, prostaglandin reduction, MAGL inhibition) suggest broader systemic relevance, though clinical evidence is confined to musculoskeletal applications. No clinical trials investigating cetyl stearate or CFA mixtures for systemic autoimmune diseases have been published in peer-reviewed journals as of the sources available.
Cetyl stearate is widely incorporated into topical formulations as an emulsifier and skin-conditioning ingredient. Its applications are diverse, serving as an emulsifier, lubricant, and stabilizer in numerous products, and it is often used as a surfactant and thickener in creams, lotions, and a range of cosmetics. In clinical CFA studies employing topical creams, application frequencies of twice daily are most commonly reported. Topical CFA formulations applied 2–3 times per day were effective in reducing pain and improving functional performance in individuals with knee or hand OA. In the knee OA postural study, cream was applied twice per day over a 30-day treatment period. In the neck MPS study, topical CFEC cream (5.6%) and 1.5% menthol or placebo cream was applied twice per day.
Dosages for oral use typically range from 1,000 to 2,000 milligrams daily. In the Hesslink et al. (2002) knee OA study, subjects received oral Celadrin (CFA), a blend of cetylated fatty acids, without a specific per-dose weight for individual esters reported. In the 2024 randomized clinical trial comparing oral CFA to meloxicam, the intervention group was prescribed a 350 mg CFA capsule three times per day for 30 days—equivalent to 1,050 mg per day total. In the 2025 European Journal of Clinical Nutrition trial, participants received 1.5 g of oral CFA or a placebo for 60 days.
In the shoulder tendinopathy study, patients used 1 patch containing CFA for 8 hours per day for 10 days. Transdermal patch delivery represents a newer dosage form designed to provide sustained, localized exposure.
Beyond its role as a potentially active component of CFA mixtures, cetyl stearate is also used as a formulation excipient. Some typical applications of cetyl stearate include its use as a lubricant, dispersing agent, and emulsion stabilizer. In tablet and capsule manufacturing, it may serve as a lubricant to facilitate processing, analogous to other waxy excipients.
The most rigorous formal safety assessment of cetyl stearate and its close structural relatives was conducted by the Cosmetic Ingredient Review (CIR) Expert Panel. The CIR Expert Panel assessed the safety of 237 alkyl esters for use in cosmetics; the Panel reviewed available animal and clinical data in making its determination of safety on these ingredients, and where there were data gaps, similarity in structure, properties, functions, and uses of these ingredients allowed for extrapolation of available toxicological data to assess the safety of the entire group; the Panel concluded that these ingredients are safe in cosmetic formulations in the present practices of use and concentration when formulated to be nonirritating.
Stearate esters, as assessed by the CIR, had low acute oral toxicity and were essentially nonirritating to the eyes when tested at and above use concentrations; at cosmetic use concentrations, the stearate esters were, at most, minimally irritating to skin. In clinical studies, the stearate esters and cosmetics and personal care products containing them were, at most, minimally to mildly irritating, essentially nonsensitizing, nonphototoxic, and nonphotosensitizing.
The CIR Expert Panel indicated that comedogenicity—the chance that an ingredient or product will cause pores in the skin to clog, possibly resulting in blackheads or whiteheads (comedones)—should be considered when using the stearate ester ingredients in cosmetic formulations. This is a formulation consideration rather than a systemic safety concern.
No adverse events were observed or reported during one randomized clinical trial in those treated with oral CFA. In the hand OA trial, adverse reactions were reported by two patients in the placebo group, whereas no such reports were documented in the CFA group. Safety studies suggest a low toxicity level; however, more research is needed to establish safe usage parameters, especially for vulnerable populations.
The European Food Safety Authority (EFSA) published a scientific opinion regarding the safety of cetyl myristoleate complex as a food ingredient; this report summarized that performed studies exhibit limitations and that potential toxicological effects of cetyl myristoleate have not been fully evaluated, concluding that the safety of "cetyl myristoleate complex" has not been established. This conclusion applies specifically to cetyl myristoleate complex and highlights that regulatory safety assessments for the full CFA class remain incomplete. Cetyl stearate per se has not been evaluated by EFSA as an isolated oral ingredient.
Long-standing use of cetyl stearate in food and supplement manufacturing underscores its safety profile, as it is generally recognized as safe (GRAS) by several regulatory authorities. Its hydrolytic breakdown products—cetyl alcohol and stearic acid—are both endogenous or common dietary fatty substances that are well-characterized metabolically.
No peer-reviewed clinical studies have documented specific pharmacokinetic drug interactions for cetyl stearate or the CFA class. Given that CFAs share a proposed mechanism overlapping with prostaglandin pathways, some researchers have speculated about additive or synergistic effects when combined with NSAIDs, but no controlled interaction studies have been published. There have been no direct comparisons of cetylated fatty acids with other supplements like glucosamine. The absence of documented interactions should not be interpreted as confirmed safety in polypharmacy contexts; no interaction studies have been completed.
In the United States, cetyl stearate is used as a cosmetic ingredient and is an approved direct food additive for certain applications. It is listed in the International Nomenclature of Cosmetic Ingredients (INCI) as CETYL STEARATE. Cetyl esters is indicated in the International Cosmetic Ingredient Dictionary and Handbook as a synthetic wax composed of a mixture of esters of saturated fatty acids and fatty alcohols with carbon chain lengths between 14 and 18; the CIR Expert Panel reviewed this ingredient in 1997 and concluded that cetyl esters is safe as used in cosmetics. When appearing as part of oral dietary supplement formulations (particularly CFA blends), it falls under the regulatory framework for dietary supplements and is not subject to pre-market approval in the United States under the Dietary Supplement Health and Education Act (DSHEA) of 1994.
Several important limitations constrain conclusions about cetyl stearate specifically:
Health conditions that Cetyl stearate may help support.
Body systems that Cetyl stearate may help support.
Go back